COMMUNIQUÉS West-GlobeNewswire
-
LIDDS: New website and change of web address
02/11/2017 - 16:13 -
Sanofi and Alnylam present positive complete results from APOLLO Phase 3 study of investigational patisiran in hereditary ATTR (hATTR) amyloidosis patients with polyneuropathy
02/11/2017 - 15:45 -
Sanofi et Alnylam présentent les résultats positifs complets de l'étude de phase 3 APOLLO consacrée à l'agent expérimental patisiran dans le traitement de l'amylose héréditaire à transthyrétine ave...
02/11/2017 - 15:45 -
Solon Eiendom ASA : Invitation to presentation of third quarter 2017 results
02/11/2017 - 15:15 -
Solon Eiendom ASA : Invitasjon til presentasjon av 3.kvartal 2017
02/11/2017 - 15:15 -
Medtronic Evolut(TM) PRO TAVR System with Advanced Sealing Maintains Excellent Outcomes Over Time
02/11/2017 - 15:00 -
Vistin Pharma ASA : Minutes from Extraordinary General Meeting
02/11/2017 - 13:45 -
Genedrive PLC: Update on Distribution arrangements for India / SAARC
02/11/2017 - 13:00 -
NuCana plc to Present at the Jefferies 2017 London Healthcare Conference
02/11/2017 - 13:00 -
AC Immune SA to Receive Milestone Payment for Anti-Tau Antibody Moving into Phase 2 Trial for Alzheimer's Disease
02/11/2017 - 11:22 -
Affimed to Present at the 26th Annual Credit Suisse Healthcare Conference
02/11/2017 - 10:58 -
Navamedic ASA: Invitation to presentation of third quarter results 2017
02/11/2017 - 10:20 -
Navamedic ASA: Invitation to presentation of third quarter results 2017
02/11/2017 - 09:48 -
Photocure ASA:U.S. CMS improves reimbursement for Blue Light Cystoscopy with Cysview®
02/11/2017 - 08:07 -
Notice to Attend the Extraordinary General Meeting of Immunicum
02/11/2017 - 07:40 -
Zealand reports royalty revenue for the third quarter of 2017
02/11/2017 - 07:39 -
Galapagos moving forward in CF programs at NACFC 2017
02/11/2017 - 07:30 -
The Board of Directors of Immunicum AB (publ) Resolves on a 90% Secured Rights Issue of up to SEK 223 Million to Finance Further Development of its Portfolio
02/11/2017 - 07:30 -
Sanofi : Q3 2017 Business EPS up 1.1% at CER FY 2017 Guidance Confirmed
02/11/2017 - 07:29
Pages